相关实验视频

Updated: Jan 13, 2026

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

埃索苏西米德和易怒肠综合征相关的腹痛:一项随机临床试验

Nicolas Kerckhove¹, Frank Zerbib², Marion Chambaz³

¹Université Clermont Auvergne, INSERM, UMR 1107 - NEURO-DOL, CIC 1405, CHU Clermont-Ferrand, Service de Gastroentérologie, Service de Pharmacologie Médicale, Direction de la Recherche Clinique et de l'Innovation, Clermont-Ferrand, France.

JAMA network open

|January 8, 2026

概括

在临床试验中,Ethosuximide是一种T型通道阻塞剂,未能有效治疗刺激性肠综合征 (IBS) 的腹痛. 该药物与安慰剂相比没有显著的益处,并且副作用更严重,表明需要更好的IBS疼痛治疗.

科学领域:

胃肠病学胃肠病学
药理学药理学是指药理学的学科.
神经学神经学

背景情况:

T型通道,特别是Cav3.2,参与疼痛信号传递.
增加的T型通道活性与刺激性肠综合征 (IBS) 中的内脏过敏相关.
抑制T型通道可能会缓解IBS相关的疼痛.

研究的目的:

评估埃索苏西米德作为治疗IBS腹痛的疗效和安全性.
乙苏胺是一种已知的T型通道阻塞剂.

主要方法:

一个多中心,双盲,安慰剂控制的随机试验.
符合Rome IV标准的IBS有显著的腹痛的成年人被纳入.
参与者接受了12周的埃索苏西米德或安慰剂.

主要成果:

乙素胺和安慰剂组之间的响应率相似 (26.6%与23.3%).
埃索苏西米德与明显更高的断药率相关 (46.9%与21.7%相比).
不良事件,包括头痛,睡眠障碍和恶心,在ethosuximide中更频繁.

结论:

与安慰剂相比,ethosuximide在治疗IBS腹痛方面没有被证明是有效的.
药物表现出较差的耐受性和增加的不良事件.
需要进一步的研究来开发更有选择性和耐受性的T型通道调节器来治疗IBS疼痛.

更多相关视频

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

相关概念视频

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Irritable Bowel Syndrome III: Medical and Nursing Management

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.

Assessment of the Gastrointestinal System I: Subjective Data

Assessment of the Gastrointestinal System I: Subjective Data

Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...